$Harrow (HROW.US)$Second Quarter 2024 and Recent Selected Highlights: ● Record revenues of $48.9 million ● GAAP net loss of $(6.5) million ● Adjusted EBITDA of $8.8 million ● Cash and cash equivalents of $71.0 million as of June 30, 2024 ● IHEEZO® customer unit demand volume increased by 98% from the first quarter of 2024 ● IHEEZO supply agreements total 24 agreements to date in 2024, including a recent win with the largest and highest volume U.S. retina practice group ● VEVYE® total prescriptions increased by 212% from the first quarter of 2024 ● Anterior Segment revenues up over 40% from the first quarter of 2024 ● Record quarterly revenues from Harrow’s ImprimisRx subsidiary
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.